Navigation Links
Alara Receives FDA Clearance to Market CRystalView T-Series CR system
Date:11/26/2007

Compact Computed Radiography Imaging System Offers Versatility And Image

Quality for a Wide Range of Specialty and Desktop Applications

CHICAGO, Nov. 26 /PRNewswire/ -- MCCORMICK PLACE, HALL A, BOOTH #3382 -- Alara Inc., a leading manufacturer of Computed Radiography (CR) medical imaging products, today announced it is showcasing the CRystalView T-Series desktop CR system at RSNA 2007 in Chicago. Alara, Inc. has received US Food and Drug Administration clearance to market the CRystalView T-Series CR system, and the system is also CE marked under the European Medical Devices Directive.

CRystalView T-Series system combines a compact rugged design, with outstanding image quality, making the solution ideal for a variety of clinical settings including radiology offices, clinics, and specialty practices like podiatry and chiropractic applications.

"Bringing new products like the CRystalView T-Series into the radiology marketplace validates our position as a leader in the CR field and helps us achieve Alara's goal of becoming the market leader in computed radiography products for all markets," explained Jim Walker, CEO, Alara, Inc. "Receiving regulatory approval to sell the CRystalView T-Series system is another step for Alara towards meeting that goal, and we look forward to building on the success of our other products including CRystalView R200 (General Radiology), DenOptix (Dental Markets), MetriScan (BMD Scanning) and the T100 (Security and NDT applications)."

At RSNA 2007 Alara will also be showcasing the CRystalView R200 system that is fast becoming the CR of choice for imaging professionals where excellent image quality combined with fast throughput is a requirement. CRystalView R200 offers imaging professionals the best of both worlds -- a compact tabletop CR system that frees up valuable floor space in size constrained radiology departments, and, image quality that is competitive with any hospital based system. "Our customers now have a choice of CR platforms that gives them unrivalled flexibility to match the CR reader of choice with the required application," added Kuldip K. Ahluwalia, VP of Sales and Marketing, Alara, Inc.

Alara has an unparalleled reputation for designing award winning products that are easy to site and simple to operate, making them suitable for office practices, clinics, imaging centers and radiology departments. Installation and training typically requires less than a single day.

CRystalView R200, MetriScan and CRystalView T-Series CR Systems are available for sale immediately. During RSNA 2007, all products will be demonstrated at the Alara exhibit in Booth #3382, Hall A- South Building, McCormick Place, Chicago, IL. For more information about CRystalView R200, CRystalView T-Series or any of Alara's other CR products, go to http://www.alara.com.

About Alara, Inc.:

Alara, Inc. is a privately held medical technology company that designs, manufactures and markets high quality imaging products based on Computed Radiography (CR) technology. Alara imaging systems are found in dental offices, orthopedic clinics, radiology departments, emergency rooms, ICUs and other healthcare operations, and are also marketed through various OEM partnerships. Alara is headquartered in Fremont, California. For more information on the company, visit http://www.alara.com


'/>"/>
SOURCE Alara, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: